Kezar Life Sciences Files 8-K on Material Agreements

Ticker: KZR · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1645666

Kezar Life Sciences, INC. 8-K Filing Summary
FieldDetail
CompanyKezar Life Sciences, INC. (KZR)
Form Type8-K
Filed DateDec 3, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, rights-modification

Related Tickers: KZR

TL;DR

Kezar Life Sciences (KZR) filed an 8-K on Dec 3rd for a material agreement - details TBD.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on December 3, 2024, reporting a material definitive agreement and material modifications to the rights of security holders. The filing does not contain specific details about the agreement or modifications, only that they occurred on or before December 3, 2024.

Why It Matters

This 8-K filing indicates significant corporate actions by Kezar Life Sciences, potentially impacting its business operations and shareholder rights.

Risk Assessment

Risk Level: medium — The filing indicates material changes, but the lack of specific details introduces uncertainty about the nature and impact of these changes.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Kezar Life Sciences?

The filing does not specify the details of the material definitive agreement, only that one was entered into.

What are the material modifications to the rights of security holders?

The filing states that material modifications to the rights of security holders occurred, but does not provide specific details.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on December 03, 2024.

What is the principal executive office address for Kezar Life Sciences?

The address is 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.

What is the telephone number for Kezar Life Sciences?

The telephone number is 650 822-5600.

Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-12-03 16:45:06

Key Financial Figures

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information set forth under "Item 3.03 Material Modification to Rights of Security Holders" of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.

03 Material Modification to Rights of Security Holders

Item 3.03 Material Modification to Rights of Security Holders. On December 3, 2024, Kezar Life Sciences, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Rights Agreement, dated as of October 17, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the "Rights Agreement"). The Amendment makes certain technical amendments to the rights and obligations of the Board of Directors of the Company to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated by reference into this Item 3.03.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Amendment No. 1, dated as of December 3, 2024, to Rights Agreement, dated as of October 17, 2024, by and between Kezar Life Sciences, Inc. and Computershare Trust Company, N.A., as Rights Agent 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: December 3, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing